Ines Deleu

5.7k total citations · 1 hit paper
15 papers, 957 citations indexed

About

Ines Deleu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Ines Deleu has authored 15 papers receiving a total of 957 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Ines Deleu's work include Advanced Breast Cancer Therapies (8 papers), Cancer Treatment and Pharmacology (8 papers) and Estrogen and related hormone effects (5 papers). Ines Deleu is often cited by papers focused on Advanced Breast Cancer Therapies (8 papers), Cancer Treatment and Pharmacology (8 papers) and Estrogen and related hormone effects (5 papers). Ines Deleu collaborates with scholars based in Belgium, United States and France. Ines Deleu's co-authors include Patrick Neven, Mario Campone, Gabriel N. Hortobágyi, Hope S. Rugo, Martine Piccart, Howard A. Burris, Louise Provencher, Mikhail Shtivelband, Shinzaburo Noguchi and Alejandra Perez and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Ines Deleu

15 papers receiving 931 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

2014 407 citations Martine Piccart, Gabriel N. Hortobágyi et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Ines Deleu

Since Specialization

Citations

This map shows the geographic impact of Ines Deleu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ines Deleu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ines Deleu more than expected).

Fields of papers citing papers by Ines Deleu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ines Deleu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ines Deleu. The network helps show where Ines Deleu may publish in the future.

Co-authorship network of co-authors of Ines Deleu

This figure shows the co-authorship network connecting the top 25 collaborators of Ines Deleu. A scholar is included among the top collaborators of Ines Deleu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ines Deleu. Ines Deleu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial 2019 ·The Lancet Oncology ·Robert E. Coleman, Dianne M. Finkelstein, Carlos H. Barrios, Miguel Martín, Hiroji Iwata, Roberto Hegg, John A. Glaspy, (unknown), Katia Tonkin, Ines Deleu, Joohyuk Sohn, John Crown, Suzette Delaloge, Tian Dai, Ying Zhou, Danielle Jandial, Arlene Chan	158
2	Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the “SOLE” trial. 2018 ·Journal of Clinical Oncology ·Elena Guerini‐Rocco, Kathryn P. Gray, Elisabetta Munzone, Caterina Fumagalli, (unknown), (unknown), (unknown), Giuseppe Viale, Patrick Neven, Erika Hitre, Guy Jérusalem, Edda Simoncini, Andrea Gombos, Ines Deleu, Angelo Di Leo, Aron Goldhirsch, Massimo Barberis, Meredith M. Regan, Marco Colleoni	1
3	Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 breakdown → 2014 ·Annals of Oncology ·Martine Piccart, Gabriel N. Hortobágyi, Mario Campone, Kathleen I. Pritchard, Fabienne Lebrun, Yoshiaki Ito, Shinzaburo Noguchi, Alejandra Perez, Hope S. Rugo, Ines Deleu, Howard A. Burris, Louise Provencher, Patrick Neven, Michael Gnant, Mikhail Shtivelband, Cheng-Han Wu, Jiaxin Fan, Wentao Feng, T Taran, José Baselga	407
4	Assessment of Genetic Alterations in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer from the BOLERO-2 Trial by Next-Generation Sequencing 2013 ·Annals of Oncology ·M. Piccart, Hope S. Rugo, (unknown), Mario Campone, Howard A. Burris, Tanya Taran, Tarek Sahmoud, Ines Deleu, Gabriel N. Hortobágyi, José Baselga	8
5	Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2 2013 ·Breast Cancer Research and Treatment ·J. Thaddeus Beck, Gabriel N. Hortobágyi, Mario Campone, Fabienne Lebrun, Ines Deleu, Hope S. Rugo, Barbara Pistilli, Norikazu Masuda, Lowell L. Hart, Bohuslav Melichar, Shaker R. Dakhil, Matthias Geberth, (unknown), Daniel Y.C. Heng, Thomas Brechenmacher, Mona El-Hashimy, (unknown), François Ringeisen, Martine Piccart	75
6	Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2. 2013 ·Journal of Clinical Oncology ·Gabriel N. Hortobágyi, Martine Piccart, Hope S. Rugo, Howard A. Burris, Mario Campone, Shinzaburo Noguchi, Alejandra Perez, Ines Deleu, Mikhail Shtivelband, Louise Provencher, Norikazu Masuda, Shaker R. Dakhil, Ian C. Anderson, David Chen, Amy Damask, Alan Huang, (unknown), Tanya Taran, Tarek Sahmoud, José Baselga	59
7	Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. 2013 ·Journal of Clinical Oncology ·Yoshinori Ito, Shinzaburo Noguchi, Ines Deleu, José Baselga, Gabriel N. Hortobágyi, Thomas Bachelot, Norikazu Masuda, Barbara Pistilli, Kathleen I. Pritchard, Hiroji Iwata, Michael Gnant, Janice F. Eakle, Tibor Csőszi, Vichien Srimuninnimit, Puttisak Puttawibul, Fausto Roila, Ashok Panneerselvam, Tanya Taran, Tarek Sahmoud, Hope S. Rugo	7
8	Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2. 2013 ·Journal of Clinical Oncology ·Hope S. Rugo, Gabriel N. Hortobágyi, Martine Piccart, Howard A. Burris, Mario Campone, Shinzaburo Noguchi, Alejandra Perez, Ines Deleu, Mikhail Shtivelband, Louise Provencher, Norikazu Masuda, Shaker R. Dakhil, Ian Anderson, David Chen, Amy Damask, Alan Huang, (unknown), Tanya Taran, Tarek Sahmoud, José Baselga	1
9	Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2. 2013 ·Journal of Clinical Oncology ·Gabriel N. Hortobágyi, Martine Piccart, Hope S. Rugo, Howard A. Burris, Mario Campone, Shinzaburo Noguchi, Alejandra Perez, Ines Deleu, Mikhail Shtivelband, Louise Provencher, Norikazu Masuda, Shaker R. Dakhil, Ian Anderson, David Chen, Amy Damask, Alan Huang, (unknown), Tanya Taran, Tarek Sahmoud, José Baselga	54
10	A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. 2012 ·PubMed ·Harry Bleiberg, A. Vandebroek, Ines Deleu, Philippe Vergauwe, (unknown), Geert D’Haens, M. Paesmans, Marc Peeters, André Efira, Yves Humblet	9
11	Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial 2011 ·Clinical Breast Cancer ·Antonio Llombart‐Cussac, Antonio Frassoldati, Outi Paija, H.P. Sleeboom, Guy Jérusalem, Jeroen Mebis, Ines Deleu, J. Miller, (unknown), Patrick Neven	108
12	A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. 2011 ·Journal of Clinical Oncology ·Xuan Bich Trinh, (unknown), Steven Van Laere, A. Prové, Ines Deleu, Marika Rasschaert, Helgi van de Velde, Pierre J. Vinken, P. Vermeulen, Peter A. van Dam, (unknown), (unknown), Wiebren Tjalma, Luc Dirix	25
13	Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial. 2011 ·Journal of Clinical Oncology ·J. Baselga, Mario Campone, Martine Piccart, H.A. Burris, H. S. Rugo, (unknown), Michael Gnant, K. I. Pritchard, Fabienne Lebrun, J. Thaddeus Beck, (unknown), DA Yardley, Ines Deleu, (unknown), Thomas Bachelot, (unknown), Pabak Mukhopadhyay, Denis Weber, Tarek Sahmoud, G. N. Hortobagyi	2
14	A Phase II Study of the Combination of Endocrine Treatment and Bortezomib in Patients with Endocrine Resistant Metastatic Breast Cancer. 2009 ·Cancer Research ·(unknown), Steven Van Laere, Ines Deleu, Helgi van de Velde, Ilse Van der Auwera, Ridha Limame, (unknown), (unknown), (unknown), Peter A. van Dam, A. Prové, J. Vandebroek, Marika Rasschaert, P Vermeulen, Luc Dirix	15
15	2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let) 2007 ·European Journal of Cancer Supplements ·Natasha Schenk, (unknown), (unknown), Patrick Neven, Guy Jérusalem, Ines Deleu, Jeroen Mebis, Marie Maerevoet, J. Miller, Rogério Dias	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact